BR112022019769A2 - Composições de rna que direcionam claudina-18.2 - Google Patents
Composições de rna que direcionam claudina-18.2Info
- Publication number
- BR112022019769A2 BR112022019769A2 BR112022019769A BR112022019769A BR112022019769A2 BR 112022019769 A2 BR112022019769 A2 BR 112022019769A2 BR 112022019769 A BR112022019769 A BR 112022019769A BR 112022019769 A BR112022019769 A BR 112022019769A BR 112022019769 A2 BR112022019769 A2 BR 112022019769A2
- Authority
- BR
- Brazil
- Prior art keywords
- claudin
- cancer
- rna
- technologies
- rna technologies
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000005516 engineering process Methods 0.000 abstract 4
- 230000008685 targeting Effects 0.000 abstract 2
- 206010004593 Bile duct cancer Diseases 0.000 abstract 1
- 206010062878 Gastrooesophageal cancer Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- -1 but not limited to Diseases 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 206010017758 gastric cancer Diseases 0.000 abstract 1
- 201000006974 gastroesophageal cancer Diseases 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 201000011549 stomach cancer Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
COMPOSIÇÕES DE RNA QUE DIRECIONAM CLAUDINA-18.2. A presente divulgação fornece tecnologias de RNA para direcionar polipeptídeos Claudina-18.2. Em algumas modalidades, essas tecnologias de RNA podem ser úteis para o tratamento de doenças associadas à expressão positiva de Claudina-18.2. Por exemplo, em algumas modalidades, tais tecnologias de RNA podem ser úteis para o tratamento de câncer positivo para Claudina-18.2, incluindo, por exemplo, mas sem limitação, câncer biliar, câncer de ovário, câncer gástrico, câncer gastroesofágico e câncer pancreático. Em algumas modalidades, tais tecnologias de RNA podem ser usadas em terapia de combinação (por exemplo, em combinação com um agente quimioterapêutico).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063002287P | 2020-03-30 | 2020-03-30 | |
PCT/EP2021/058112 WO2021198157A1 (en) | 2020-03-30 | 2021-03-29 | Rna compositions targeting claudin-18.2 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022019769A2 true BR112022019769A2 (pt) | 2022-12-13 |
Family
ID=75302588
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022019769A BR112022019769A2 (pt) | 2020-03-30 | 2021-03-29 | Composições de rna que direcionam claudina-18.2 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20240043527A1 (pt) |
EP (1) | EP4126947A1 (pt) |
JP (1) | JP2023520062A (pt) |
KR (1) | KR20220161316A (pt) |
CN (1) | CN115397856A (pt) |
AR (1) | AR121691A1 (pt) |
AU (1) | AU2021250814A1 (pt) |
BR (1) | BR112022019769A2 (pt) |
CA (1) | CA3174588A1 (pt) |
IL (1) | IL296781A (pt) |
MX (1) | MX2022012105A (pt) |
WO (1) | WO2021198157A1 (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL303195A (en) | 2020-11-25 | 2023-07-01 | Akagera Medicines Inc | Lipid nanoparticles for delivery of nucleic acids and related methods of use |
WO2023230295A1 (en) * | 2022-05-25 | 2023-11-30 | BioNTech SE | Rna compositions for delivery of monkeypox antigens and related methods |
CN114989182B (zh) * | 2022-06-23 | 2023-06-23 | 尧唐(上海)生物科技有限公司 | 脂质化合物、包含其的组合物及应用 |
WO2024074634A1 (en) * | 2022-10-06 | 2024-04-11 | BioNTech SE | Rna compositions targeting claudin-18.2 |
WO2024074211A1 (en) * | 2022-10-06 | 2024-04-11 | BioNTech SE | Rna compositions targeting claudin-18.2 |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5965542A (en) | 1997-03-18 | 1999-10-12 | Inex Pharmaceuticals Corp. | Use of temperature to control the size of cationic liposome/plasmid DNA complexes |
EP1053023B2 (en) | 1998-02-03 | 2011-03-30 | Protiva Biotherapeutics Inc. | Systemic delivery of serum stable plasmid lipid particles for cancer therapy |
US6410328B1 (en) | 1998-02-03 | 2002-06-25 | Protiva Biotherapeutics Inc. | Sensitizing cells to compounds using lipid-mediated gene and compound delivery |
US6211140B1 (en) | 1999-07-26 | 2001-04-03 | The Procter & Gamble Company | Cationic charge boosting systems |
JP4722481B2 (ja) | 2002-06-28 | 2011-07-13 | プロティバ バイオセラピューティクス リミテッド | リポソーム製造方法および装置 |
CA2532228C (en) | 2003-07-16 | 2017-02-14 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering rna |
US6927663B2 (en) | 2003-07-23 | 2005-08-09 | Cardiac Pacemakers, Inc. | Flyback transformer wire attach method to printed circuit board |
JP4842821B2 (ja) | 2003-09-15 | 2011-12-21 | プロチバ バイオセラピューティクス インコーポレイティッド | ポリエチレングリコール修飾脂質化合物およびその使用 |
WO2005120152A2 (en) | 2004-06-07 | 2005-12-22 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods of use |
US7799565B2 (en) | 2004-06-07 | 2010-09-21 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering RNA |
CN101267805A (zh) | 2005-07-27 | 2008-09-17 | 普洛体维生物治疗公司 | 制造脂质体的***和方法 |
EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
DE102007001370A1 (de) * | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
EP1997832A1 (en) | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against Claudin-18 for treatment of cancer |
CA3044134A1 (en) | 2008-01-02 | 2009-07-09 | Arbutus Biopharma Corporation | Improved compositions and methods for the delivery of nucleic acids |
DK2279254T3 (en) | 2008-04-15 | 2017-09-18 | Protiva Biotherapeutics Inc | PRESENT UNKNOWN LIPID FORMS FOR NUCLEIC ACID ADMINISTRATION |
MX359674B (es) | 2008-11-10 | 2018-10-05 | Alnylam Pharmaceuticals Inc | Lipidos y composiciones novedosas para el suministro de terapeuticos. |
WO2011000106A1 (en) | 2009-07-01 | 2011-01-06 | Protiva Biotherapeutics, Inc. | Improved cationic lipids and methods for the delivery of therapeutic agents |
IL292615B2 (en) | 2009-07-01 | 2023-11-01 | Protiva Biotherapeutics Inc | Nucleic acid-lipid particles, preparations containing them and their uses |
US20130022649A1 (en) | 2009-12-01 | 2013-01-24 | Protiva Biotherapeutics, Inc. | Snalp formulations containing antioxidants |
EP3296398A1 (en) | 2009-12-07 | 2018-03-21 | Arbutus Biopharma Corporation | Compositions for nucleic acid delivery |
ES2749426T3 (es) | 2009-12-18 | 2020-03-20 | Univ British Columbia | Métodos y composiciones para administración de ácidos nucleicos |
WO2011141705A1 (en) | 2010-05-12 | 2011-11-17 | Protiva Biotherapeutics, Inc. | Novel cationic lipids and methods of use thereof |
KR101967411B1 (ko) | 2010-06-03 | 2019-04-10 | 알닐람 파마슈티칼스 인코포레이티드 | 활성제의 전달을 위한 생분해성 지질 |
WO2012016184A2 (en) | 2010-07-30 | 2012-02-02 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for delivery of active agents |
US8466122B2 (en) | 2010-09-17 | 2013-06-18 | Protiva Biotherapeutics, Inc. | Trialkyl cationic lipids and methods of use thereof |
EP3202760B1 (en) | 2011-01-11 | 2019-08-21 | Alnylam Pharmaceuticals, Inc. | Pegylated lipids and their use for drug delivery |
US8691750B2 (en) | 2011-05-17 | 2014-04-08 | Axolabs Gmbh | Lipids and compositions for intracellular delivery of biologically active compounds |
WO2013016058A1 (en) | 2011-07-22 | 2013-01-31 | Merck Sharp & Dohme Corp. | Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery |
CA2849476A1 (en) | 2011-09-27 | 2013-04-04 | Alnylam Pharmaceuticals, Inc. | Di-aliphatic substituted pegylated lipids |
US8762704B2 (en) | 2011-09-29 | 2014-06-24 | Apple Inc. | Customized content for electronic devices |
US20140308304A1 (en) | 2011-12-07 | 2014-10-16 | Alnylam Pharmaceuticals, Inc. | Lipids for the delivery of active agents |
US9061063B2 (en) | 2011-12-07 | 2015-06-23 | Alnylam Pharmaceuticals, Inc. | Biodegradable lipids for the delivery of active agents |
US9463247B2 (en) | 2011-12-07 | 2016-10-11 | Alnylam Pharmaceuticals, Inc. | Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents |
AU2012352180A1 (en) | 2011-12-16 | 2014-07-31 | Moderna Therapeutics, Inc. | Modified nucleoside, nucleotide, and nucleic acid compositions |
WO2013167153A1 (en) * | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Antibodies useful in cancer diagnosis |
WO2013174403A1 (en) | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
WO2014008334A1 (en) | 2012-07-06 | 2014-01-09 | Alnylam Pharmaceuticals, Inc. | Stable non-aggregating nucleic acid lipid particle formulations |
HUE060907T2 (hu) | 2014-06-25 | 2023-04-28 | Acuitas Therapeutics Inc | Új lipidek és lipid nanorészecske formulációk nukleinsavak bevitelére |
WO2016005004A1 (en) | 2014-07-11 | 2016-01-14 | Biontech Rna Pharmaceuticals Gmbh | Stabilization of poly(a) sequence encoding dna sequences |
DK3313829T3 (da) | 2015-06-29 | 2024-06-17 | Acuitas Therapeutics Inc | Lipider og lipide nanopartikelformuleringer til levering af nukleinsyrer |
CN116751827B (zh) | 2015-09-21 | 2024-01-30 | 垂林克生物技术有限公司 | 用于合成5’-加帽rna的组合物和方法 |
WO2017059902A1 (en) | 2015-10-07 | 2017-04-13 | Biontech Rna Pharmaceuticals Gmbh | 3' utr sequences for stabilization of rna |
HUE061564T2 (hu) | 2015-10-28 | 2023-07-28 | Acuitas Therapeutics Inc | Új lipidek és lipid nanorészecske készítmények nukleinsavak bevitelére |
RU2760790C2 (ru) | 2016-04-22 | 2021-11-30 | Бионтэк Рна Фармасьютикалз Гмбх | Способы получения одноцепочечной рнк |
EP3532103A1 (en) | 2016-10-26 | 2019-09-04 | Acuitas Therapeutics, Inc. | Lipid nanoparticle formulations |
AU2019270865B2 (en) * | 2018-05-18 | 2023-03-30 | LaNova Medicines Limited | Anti-claudin 18.2 antibodies and uses thereof |
-
2021
- 2021-03-29 CA CA3174588A patent/CA3174588A1/en active Pending
- 2021-03-29 JP JP2022559917A patent/JP2023520062A/ja active Pending
- 2021-03-29 IL IL296781A patent/IL296781A/en unknown
- 2021-03-29 US US17/915,567 patent/US20240043527A1/en active Pending
- 2021-03-29 WO PCT/EP2021/058112 patent/WO2021198157A1/en unknown
- 2021-03-29 CN CN202180025888.2A patent/CN115397856A/zh active Pending
- 2021-03-29 KR KR1020227033509A patent/KR20220161316A/ko unknown
- 2021-03-29 EP EP21715591.0A patent/EP4126947A1/en active Pending
- 2021-03-29 AU AU2021250814A patent/AU2021250814A1/en active Pending
- 2021-03-29 BR BR112022019769A patent/BR112022019769A2/pt not_active Application Discontinuation
- 2021-03-29 MX MX2022012105A patent/MX2022012105A/es unknown
- 2021-03-30 AR ARP210100787A patent/AR121691A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
CA3174588A1 (en) | 2021-10-07 |
KR20220161316A (ko) | 2022-12-06 |
US20240043527A1 (en) | 2024-02-08 |
AU2021250814A1 (en) | 2022-10-13 |
EP4126947A1 (en) | 2023-02-08 |
IL296781A (en) | 2022-11-01 |
AR121691A1 (es) | 2022-06-29 |
CN115397856A (zh) | 2022-11-25 |
WO2021198157A1 (en) | 2021-10-07 |
MX2022012105A (es) | 2022-10-18 |
JP2023520062A (ja) | 2023-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022019769A2 (pt) | Composições de rna que direcionam claudina-18.2 | |
PH12020551923A1 (en) | Methods and compositions for treating cancer | |
CL2023003068A1 (es) | Compuestos, composiciones y métodos para el tratamiento de trastornos | |
MX2019011506A (es) | Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer. | |
BR112019022280A2 (pt) | tratamento de cânceres de her2 positivo | |
BR112021011684A2 (pt) | Terapia combinada com cd70 e venetoclax, um inibidor de bcl-2, para o tratamento da leucemia mieloide aguda | |
MX2020012679A (es) | Compuestos de amino-pirazincarboxamida, conjugados, y usos de los mismos. | |
BRPI0510657A (pt) | tratamento com cisplatina e com um inibidor de egfr | |
BR0012677A (pt) | Ativação terapêutica catalisada por enzima | |
BR112021015036A2 (pt) | Tratamento para câncer com imunoconjugados do anticorpo ror1 | |
BRPI0507463A (pt) | uso de glufosfamide e gemcitabine , produto, e, combinação de glufosfamide e gemcitabine | |
BR112023021561A2 (pt) | Compostos de carbóxi-benzimidazol moduladores de glp-1r | |
BR112021022784A2 (pt) | Composições e métodos para tratamento do câncer | |
BR112019023898A2 (pt) | método para tratamento de câncer gástrico, uso de um anticorpo e composição | |
BR112019023948A2 (pt) | tratamento de cistos epiteliais por injeção intracística de partículas antineoplásicas | |
BR112023005160A2 (pt) | Terapia de combinação para o tratamento de câncer | |
BR112023021913A2 (pt) | Tratamento de câncer com inibidor de raf | |
MX2021008834A (es) | Metodos de tratamiento del cancer de mama con tucatinib. | |
AR045144A1 (es) | Metodo para tratar a un paciente que tiene un neoplasma o que tiene riesgo de desarrollarlo | |
BR112022006476A2 (pt) | Oligonucleotídeos com análogos de nucleosídeos | |
MX2019012660A (es) | Metodo para tratar cancer empleando un inhibidor de proteina de linfoma de celulas b 2 (bcl-2) en forma conjunta con una radioinmunoterapia con emision de particulas alfa. | |
BR112015031950A2 (pt) | métodos para tratamento de câncer de ovário | |
DOP2023000202A (es) | Terapia de combinación que implica anticuerpos contra claudina 18.2 para el tratamiento del cáncer. | |
MX2021000935A (es) | Composiciones y metodos terapeuticos para el tratamiento de cancer pancreatico con acido 6,8-bis(bencilsulfanil)octanoico. | |
MX2022005251A (es) | Conjugados de interleuquina 10 y sus usos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |